Tags : ANNOUNCE

Myovant and Pfizer Publish the Results of Relugolix Combination Regimen

Tuba Khan February 18, 2021

Shots: The P-III LIBERTY 1 & 2 studies involve assessing of relugolix (40mg) + estradiol (1.0mg) & norethindrone acetate (0.5mg) vs PBO in women with uterine fibroids The results showed […]readmore

Biotech

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Vartika Singh January 22, 2019

Shots: The P-III ANNOUNCE study involves assessing of Lartruvo + doxorubicin following lartruvo monothx vs doxorubicin + PBO following PBO monothx in patients with advanced or metastatic STS The study […]readmore

Tags : ANNOUNCE

Myovant and Pfizer Publish the Results of Relugolix Combination Regimen

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Company

Tags : ANNOUNCE

Myovant and Pfizer Publish the Results of Relugolix Combination Regimen

Eli Lilly Reports Results of Lartruvo (olaratumab) in ANNOUNCE P-III

Latest Posts

PharmaShots Weekly Snapshots (November 15 – 19, 2021)

Jazz’ Sunosi (solriamfetol) Receives NICE Recommendation for the Treatment of Excessive Daytime Sleepiness Caused by Narcolepsy

Antengene’s Selinexor (ATG-010) Receives NMPA’s IND Approval for P-I/II SWATCH Study to Treat Non-Hodgkin Lymphoma

Daiichi Sankyo Reports Results of Quizartinib in P-III QuANTUM-First Trial for the Treatment of FLT3-ITD Positive AML

Categories

Related Topics

Company